Sarah Cannon Research Institute (SCRI) has appointed Deepak Bhamidipati, MD as Assistant Director, Drug Development. In addition to his leadership role at SCRI, Dr. Bhamidipati will serve as a medical oncologist at SCRI Oncology Partners in Nashville, Tenn. beginning on October 22.
Dr. Deepak Bhamidipati will collaborate closely with Vivek Subbiah, MD, SCRI’s Chief of Early-Phase Drug Development, to enhance the early-phase drug development program in Nashville. Dr. Bhamidipati joins SCRI from MD Anderson Cancer Center where he completed his fellowship in hematology/oncology. He was a recipient of the Conquer Cancer Foundation’s Young Investigator Award and the ASCO Merit Award for his research efforts in gastrointestinal malignancies. He completed his Doctor of Medicine at Sidney Kimmel Medical College at Thomas Jefferson University and his residency at Baylor College of Medicine.